T cell-specific inactivation of mouse CD2 by CRISPR/Cas9
Scientific Reports2016Vol. 6(1), pp. 21377–21377
Citations Over TimeTop 20% of 2016 papers
Jane Beil-Wagner, Georg Dössinger, Kilian Schober, Johannes vom Berg, Achim Tresch, Martina Grandl, Pushpalatha Palle, Florian Mair, Markus Gerhard, Burkhard Becher, Dirk H. Busch, Thorsten Buch
Abstract
The CRISPR/Cas9 system can be used to mutate target sequences by introduction of double-strand breaks followed by imprecise repair. To test its use for conditional gene editing we generated mice transgenic for CD4 promoter-driven Cas9 combined with guide RNA targeting CD2. We found that within CD4(+) and CD8(+) lymphocytes from lymph nodes and spleen 1% and 0.6% were not expressing CD2, respectively. T cells lacking CD2 carryied mutations, which confirmed that Cas9 driven by cell-type specific promoters can edit genes in the mouse and may thus allow targeted studies of gene function in vivo.
Related Papers
- → CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery(2017)550 cited
- → CRISPR-Cas9 system: A new-fangled dawn in gene editing(2019)310 cited
- → Temperature effect on CRISPR-Cas9 mediated genome editing(2017)108 cited
- → Therapeutic applications of CRISPR RNA-guided genome editing(2016)25 cited
- → CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases(2018)17 cited